Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Uncertainty Now Surrounds Cochlear
Sep 13 2011
Cochlear has recalled its Nucleus 5 device and brokers have been quick to reassess the stock given the potential impact on both earnings and reputation.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Sep 12 2011
Weekly update on recommendation, target price, and earnings forecast changes.
REVA Upside Opportunity
Sep 01 2011
REVA Medical has seen the timeline for starting clinical trials of its bioresorbable stent slip but Bell Potter says any associated share price weakness would be a buying opportunity.
Mesoblast’s Upside Significant
Aug 25 2011
Bell Potter sees significant upside potential from Mesoblast’s stem cell technology and has lifted its price target accordingly.
Asia To Drive Growth For Blackmores
Aug 22 2011
Asia is proving to be a solid driver of earnings growth for Blackmores. Post a solid FY11 result Credit Suisse has upgraded to Outperform.
Mixed Views Following Cochlear Result
Aug 11 2011
Cochlear’s full year earnings met consensus expectations but there were differing views on the result.
ResMed Outlook Dominated By FX Movements
Aug 08 2011
ResMed’s quarterly result showed enough positives to outweigh current forex pressures for a number of equity brokers.
Bionomics A Spec Buy For Anti-Anxiety Treatment
Aug 05 2011
Aussie biotech junior Bionomics has received positive results from early trials of an anti-anxiety compound and Bell Potter sees enough potential upside to rate the stock a Speculative Buy.
Blue Sky Potential Materialising For Genetic Technologies
Aug 02 2011
Genetic Technologies is a market leader in the checking of breast cancer risk and the potential upside sees RBS Morgans initiate coverage with a Buy rating.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Jul 18 2011
Weekly update on recommendation, target price, and earning forecast changes.
